If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Geographical indications protect the name of a product that has a specific geographical origin and owes its qualities, characteristics or reputation to its particular origin. Find out what they are, how the registration process works and what benefits they provide.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
337
results.
Updated on
21/08/2026 [07:27:00]
Results 275 to 300 of 337
Absstract of: WO2026145099A1
Provided in the present invention is the use of NUCB1 in the prevention and/or treatment of autoimmune diseases. Specifically provided in the present invention is the use of an NUCB1 gene, or a protein thereof, or a promoter thereof in the preparation of a composition or preparation, wherein the composition or preparation is used for preventing and/or treating autoimmune diseases. The NUCB1 gene, or the protein thereof, or the promoter thereof of the present invention can significantly prevent and/or treat autoimmune diseases, and is particularly effective against systemic lupus erythematosus, atopic dermatitis, rheumatoid arthritis, psoriasis, multiple sclerosis, or Crohn's disease.
Absstract of: CN122302156A
0001 本发明提供一种胆碱仿生双亲聚合物纳米盘，所述胆碱仿生双亲聚合物纳米盘的制备原料包括聚甲基丙烯酸酯共聚物；所述聚甲基丙烯酸酯共聚物由2‑甲基丙烯酰氧乙基磷酰胆碱与甲基丙烯酸己酯经聚合反应制备得到。该胆碱仿生双亲聚合物纳米盘具备高效穿越BBB的能力和脑靶向能力，在体外BBB模型和小鼠体内都能高效的通过胆碱转运受体跨越BBB，该胆碱仿生双亲聚合物纳米盘的盘状形态和纳米级尺寸促进了血管、基质和细胞屏障的有效渗透，具有卓越的实体瘤浸润能力。本发明提供一种上述的胆碱仿生双亲聚合物纳米盘的制备方法以及上述的胆碱仿生双亲聚合物纳米盘在制备脑肿瘤的检测试剂或脑肿瘤的预防、治疗药物中的应用。
Absstract of: CN122307112A
0001 本申请涉及一种神经退行性变标志物检测试剂及检测方法。该神经退行性变标志物检测试剂包括产氧剂、催化剂和能够与待测样本中的待测神经退行性变标志物特异性结合的免疫检测试剂；其中，产氧剂在催化剂的作用下发生反应生成氧气，生成的氧气用于增加反应体系中的氧含量；免疫检测试剂能够利用反应液中的活性氧产生光信号，待测靶分子选自神经退行性变标志物。本申请提供的方案，能够在神经退行性变标志物浓度水平较低时，提高光信号值，有利于提高对神经退行性变标志物的检出能力。
Absstract of: CN122297687A
0001 本发明提供了乳酰化修饰PRDX5蛋白及其产品和应用，属于生物医药技术领域。本发明揭示了PRDX5 K71位点乳酰化修饰在COPD病理进程中的关键作用，其在COPD小鼠海马组织神经元乳酰化水平异常升高，且与小鼠认知功能障碍的发生发展密切相关；同时提供了靶向该位点的特异性干预方案，通过立体定位注射重组腺相关病毒PRDX5 K71R突变体降低或阻断K71位点发生乳酰化修饰的可能性，可有效改善COPD小鼠的学习记忆与空间定位能力，为认知功能障碍的机制研究与靶向防治提供了新的分子靶点和实验依据。
Absstract of: AU2020258381A1
Disclosed herein are methods for detecting a biological or chemical entity in a sample, wherein the biological or chemical entity is associated with extracellular vesicles. The methods disclosed comprise the steps of a) processing the sample, (b) using a detection assay to detect the presence of extracellular vesicles and to isolate the extracellular vesicles, (c) processing the extracellular vesicles to expose or release the biological or chemical entity, and (e) detecting the biological or chemical entity released from the extracellular vesicle. In certain embodiments, the extracellular vesicles are associated with proteins, glycoproteins, peptides, lipids, nucleic acids or other cellular components. The detection methods are useful for identifying the presence of microbial antigens related to
Absstract of: US12668835B1
A sample holder includes a first member featuring a first retaining mechanism configured to retain a first substrate that includes a sample, a second member featuring a second retaining mechanism configured to retain a second substrate that includes a reagent medium, and an alignment mechanism connected to at least one of the first and second members, and configured to align the first and second members such that the sample contacts at least a portion of the reagent medium when the first and second members are aligned.
Absstract of: CN121263693A
Provided herein are methods for detecting proteins and/or protein variants thereof, the methods comprising adding to a biological sample one or more small molecules and one or more protein binding agents wherein a protein crown is formed on a surface of the protein binding agent, and detecting the protein and/or protein variants thereof in the protein crown by antibody-based technology or proteomic technology. Also provided herein are methods for detecting one or more biomarkers or patterns of one or more biomarkers associated with a disease or health profile condition, as well as methods of diagnosing or predicting a disease in a subject. Compositions comprising one or more small molecules, one or more protein binding agents, and one or more biological samples are also provided.
Absstract of: WO2025146757A1
This method for quantifying plasmalogens comprises: a measurement sample preparation step for mixing a Schiff reagent with a specimen containing protein and plasmalogens to obtain a measurement sample; a control sample preparation step for mixing the specimen with a solvent of the Schiff reagent to obtain a control sample; a measurement step for measuring the extent of a first optical property of the measurement sample, the first optical property being obtained by reacting the Schiff reagent with an aldehyde generated from vinyl ether bonds of the plasmalogens, and measuring the extent of the optical property of the control sample; and a determination step for determining the concentration of plasmalogens in the specimen by comparing the correction extent, that is the extent to which the extent of the first optical property has been corrected by the extent of the optical property of the control sample, with the extent of a second optical property of a standard sample containing the Schiff reagent and a known concentration of plasmalogens, the second optical property being the optical property after the Schiff reagent has been reacted with the aldehyde generated from the vinyl ether bonds of the plasmalogens.
Absstract of: CN122307115A
本发明提供一种生物标志物在制备轻度认知障碍风险评估产品中的用途，所述生物标志物包括Aβ寡聚体。单独的Aβ寡聚体标志物对MCI具有显著的预测价值，在区分认知正常与MCI的受试者时，其测试集受试者工作特征曲线下面积（AUC）即可达到 0.851（95% 置信区间:0.803 ‑ 0.895），证明其在区分出MCI受试者具有优越的性能。
Absstract of: KR20260099247A
본 발명은 파킨슨병 및 시누클레인병증 진단을 위한 키트 및 검출 방법에 관한 것이다. 본 발명의 키트 및 검출 방법을 이용하면 환자의 혈장을 이용하여 비침습적이면서도 높은 정확도를 가지고 파킨슨병과 시누클레인병증을 진단할 수 있다.
Absstract of: CN122282992A
本发明提供了一种测定人血浆中β‑淀粉样蛋白42/40比率的质谱方法，包括采用¹5N稳定同位素标记的完整Aβ42和Aβ40蛋白作为内标，通过免疫沉淀技术对血浆样本进行提取与纯化，并利用Lys‑N蛋白酶解产生特征性肽段，最终通过液相色谱‑串联质谱进行靶向定量分析。Aβ42的特征肽段是Aβ28‑42 KGAIIGLMVGGVVIA；Aβ40的特征肽段是Aβ28‑40 KGAIIGLMVGGVV。相较于完整蛋白，本发明中的特征肽段不易发生聚集且在质谱中具有更高的电离效率，展现出优异的特异性、重复性与灵敏度，能够为阿尔茨海默症的诊断提供可靠依据。
Absstract of: CN122283145A
本发明属于检测技术领域，本发明具体公开了一种磷酸化Tau181蛋白测定试剂盒及应用，本申请所述的抗试剂A和抗试剂B中的p‑Tau181抗体中的生物素和碱性磷酸酶发生反应，形成抗体‑抗原‑抗体复合物并通过生物素与链霉亲和素的反应结合到磁性微粒上，加入化学发光底物AMPPD，碱性磷酸酶催化AMPPD产生化学发光信号，通过光学检测系统测量发光强度，仪器自动通过工作曲线计算得出检测结果，本申请通过对试剂盒的抗试剂A和抗试剂B以及磁微粒试剂进行设计，能够精准捕获抗体并放大信号，有效的降低检测限，提升试剂盒的综合性能。
Absstract of: WO2025059487A2
The present disclosure provides cell penetrating agents comprising a cell internalization module and an antibody or antigen binding antibody fragment thereof that specifically binds to human beta amyloid and methods of using these cell penetrating agents to treat patients with beta amyloid related diseases, including Inclusion-body myositis (IBM).
Absstract of: CN122283142A
本发明公开了一种用于阿尔茨海默病早期筛查的泪液检测装置及方法，属于体外诊断医疗器械技术领域，包括泪液采样器、微流控芯片和便携式读数器，泪液采样器用于将采集并预处理的泪液样本输送至微流控芯片，微流控芯片上设置有样品输入口，泪液采样器与样品输入口连接，微流控芯片上设置有用于检测生物标志物的微通道结构，且微流控芯片能置于便携式读数器的卡槽内，便携式读数器用于进行信号检测并对监测数据进行分析后输出诊断结果。本发明采用上述的一种用于阿尔茨海默病早期筛查的泪液检测装置及方法，旨在实现阿尔茨海默病的早期、快速、高灵敏度诊断。
Absstract of: CN122277723A
0001 本发明公开了检测载脂蛋白E4的抗体及其应用，具体涉及检测阿尔茨海默症血液标志物ApoE4的检测抗体和试剂盒，基于该抗体及试剂盒能够准确的检测载脂蛋白E4的存在。
Absstract of: CN122291031A
0001 本发明公开了一种基于不良结局路径模型的污染物联合暴露毒性风险预警方法，建立联合暴露体系，将受试对象分为空白对照组、单一污染物暴露组及联合暴露组，在预设环境条件下进行暴露；在暴露过程中设置两个采样时间点，包括第一采样时间点和第二采样时间点；获取受试对象多层级检测指标数据，包括生化指标、组织病理指标、表面超微结构指标和/或基因表达指标；基于所述多层级检测指标数据，识别不良结局路径中的分子起始事件、早期关键事件、后期关键事件及不良结局，建立分子起始事件至关键事件再至不良结局的因果关联链条；根据不良结局的出现情况，输出分级风险预警结果。联合暴露体系中的受试对象为鱼类，污染物为全氟辛酸和聚苯乙烯微塑料。
Absstract of: CN122283116A
本发明公开了一种神经轻链蛋白的检测试剂盒、方法及磁性水凝胶制备方法，本发明的检测试剂盒，包含磁性水凝胶偶联探针，神经轻链蛋白检测抗体，预激发液和激发液；其中，磁性水凝胶偶联探针为表面络合有顺磁性的纳米四氧化三铁粒子的含羧基聚合物球形颗粒。
Absstract of: AU2024312747A1
The present disclosure relates method of identifying a compound targeting a first protein and a second protein, wherein the first protein and/or the second protein are associated with a disease or disorder.
Absstract of: CN122283146A
0001 本发明提供了人源卵泡抑素样蛋白（FSTL1）作为特发性正常压力脑积水标记物的应用及检测方法及试剂盒，其中，人源卵泡抑素样蛋白（FSTL1）的NCBI Gene ID 11167，RefSeq mRNA编号为NM_007085.5，RefSeq蛋白编码为NP_009016.1，UniProt编号为Q12841。本发明解决了现有检测技术中存在的无法早期分子识别、标志物特异性不足、低丰度蛋白检测灵敏度不足的技术问题。
Absstract of: CN122277725A
本申请实施例提供了一种抗NFL蛋白的单克隆抗体组合及其用途。所述单克隆抗体组合包括第一抗体和第二抗体，第一抗体包括第一重链可变区和第一轻链可变区，第二抗体包括第二重链可变区和第二轻链可变区；第一重链可变区包括如SEQ ID NO:3‑5所示的三个互补决定区，第一轻链可变区包括如SEQ ID NO:6‑8所示的三个互补决定区；第二重链可变区包括如SEQ ID NO:11‑13所示的三个互补决定区；第二轻链可变区包括如SEQ ID NO:14‑16所示的三个互补决定区。本实施例提供的单克隆抗体组合具有优异的特异性和高亲和力，可用于体外定量检测血清中NFL浓度，为神经系统相关疾病的辅助诊断提供技术支持。
Absstract of: EP4560314A1
0001 The present invention relates to an ex vivo method for mapping the spatiotemporal electrophysiological dynamics and spatial transcriptional profiles of cells in a functional neuronal cell assembly, comprising simultaneous recording and analysis of spatial data of molecular and electrical network activity down to the level of individual cells using high-density electrical biosensors, spatial transcriptomics, optical imaging, and advanced computational strategies. The invention further relates to methods for identifying the composition of a functional neuronal assembly, for monitoring the spatiotemporal electrophysiological dynamics and transcriptional profiles of cells in a functional neuronal cell assembly, for monitoring the cellular composition of a functional neuronal assembly, or for identifying a compound having an effect on the spatial electrophysiological and transcriptional dynamics and/or for identifying the composition of cells in a functional neuronal cell assembly based on the dynamics as detected, as well as devices and uses thereof. The invention allows for a better understanding of disease mechanisms, and to find therapeutic targets and to develop new drugs and treatments.
Absstract of: WO2026132535A1
The invention relates to an in vitro method for the differential diagnosis and/or prognosis of the presence or absence of a central nervous system (CNS) inflammation, in a subject with one or more symptoms of an acute neurological syndrome, said diagnosis and/or prognosis comprising: i) a CNS infection or ii) a neurological disorder without a CNS infection, or iii) an exclusion of i) and ii). The invention further relates to an in vitro method for detecting proadrenomedullin (proADM) or fragment(s) thereof in a cerebrospinal fluid sample. The invention further relates to kits for carrying out the methods of the invention.
Absstract of: WO2026132195A1
The present invention concerns the field of diagnostics. In particular, it relates to a method for analyzing a protein analyte in a heparin-treated sample comprising or suspected to comprise said protein analyte, said method comprising the step of contacting said heparin-treated sample with spermidine prior to analyzing the said protein analyte in the said sample. Moreover, contemplated are a method for assessing a cardiovascular disease or disorder, a neurological disease or disorder, a metabolic disease or disorder or cancer as well as kits and reagent compositions comprising spermidine to be used in the said methods.
Absstract of: US20260177544A1
An object of the present invention is to provide a highly sensitive method for detecting a biomarker. The object can be achieved by a method for detecting a test substance in a specimen of the present invention, the method being (A) a sandwich method including: (1) bringing a specimen into contact with a magnetic particle on which a primary substance is immobilized and which has a particle diameter that does not cause interference with a wavelength for measurement with a laser, to form a primary substance-test substance complex of the primary substance and a test substance in the specimen; (2) bringing the primary substance-test substance complex into contact with a secondary substance, to form a primary substance-test substance-secondary substance complex of the primary substance-test substance complex and the secondary substance; and (3) detecting the primary substance-test substance-secondary substance complex on the magnetic particle with a laser; or (B) a competitive method including: (1) bringing a specimen and a secondary substance into contact with a magnetic particle on which a primary substance is immobilized and which has a particle diameter that does not cause interference with a wavelength for measurement with a laser, to form a primary substance-secondary substance complex of the primary substance and the secondary substance; and (2) detecting the primary substance-secondary substance complex on the magnetic particle with a laser.
Nº publicación: US20260177568A1 25/06/2026
Applicant:
KREBS JOSEPH FRANCIS [US]
FORD LANCE PHILIP [US]
Ford Lance Philip
Krebs Joseph Francis
Absstract of: US20260177568A1
The present invention provides lateral flow assay devices and methods for detecting nicotinic acetylcholine receptor ligands in liquid samples. The device comprises a porous strip with multiple zones, including a sample deposition zone, a test visualization zone containing an immobilized nicotine conjugate, a control zone, and an absorbent zone. A recombinant acetylcholine receptor protein serves as a mobile agent, either pre-deposited on the strip or added to the sample. The recombinant protein comprises a ligand-binding domain of a nicotinic acetylcholine receptor conjugated to a visually-detectable reporter forming a receptor-reporter conjugate. When nicotinic acetylcholine receptor ligands are present in the sample, they competitively bind to the recombinant receptor protein, reducing binding to the immobilized nicotine conjugate and producing a visually detectable signal inversely proportional to ligand concentration. The invention provides rapid, simple, and field-deployable detection of receptor ligands in environmental samples, including cyanobacterial neurotoxins in surface waters, and biological samples for pharmacological and toxicological applications.
BOPI
Electronic site
